OBJECTIVE: To evaluate the operative and pathologic outcomes of laparoscopic radical prostatectomy and robot-assisted radical prostatectomy in men with progressive changes in body mass index (BMI) category. MATERIALS AND METHODS: A single-surgeon series of 1023 laparoscopic radical prostatectomy and robot-assisted radical prostatectomy (mostly extraperitoneal) patients was considered. Of these patients, 987 were evaluable. Results were stratified by the World Health Organization BMI category. Multivariate linear and logistic regression analysis was used to model the operating time, length of stay, positive surgical margins, and noncurable cancer. RESULTS: Of the 987 patients, 563 (57%) were overweight and 193 (19.6%) were obese. Of the 193 obese patients, 152 (15.4%) had a BMI of 30 to <35 kg/m(2) (class I obesity), 28 (2.8%) a BMI of 35 to <40 kg/m(2) (class II), and 13 (1.3%) a BMI of ≥40 kg/m(2) (class III). No differences were found in the estimated blood loss, complications, PSM, pathologic stage, or biochemical recurrence across the BMI categories (6-month median follow-up). However, pelvic lymph node dissection was more commonly omitted and the nerve-sparing score was inferior in the obese men. On multivariate analysis, a higher BMI was a significant predictor of a longer operating time. CONCLUSION: Obese men can safely undergo laparoscopic radical prostatectomy or robot-assisted radical prostatectomy, although the ability to perform excellent nerve sparing appears to decrease with increasing obesity. Nevertheless, obese men can expect perioperative and early oncologic outcomes comparable to those of normal weight men without an increased risk of perioperative complications.
OBJECTIVE: To evaluate the operative and pathologic outcomes of laparoscopic radical prostatectomy and robot-assisted radical prostatectomy in men with progressive changes in body mass index (BMI) category. MATERIALS AND METHODS: A single-surgeon series of 1023 laparoscopic radical prostatectomy and robot-assisted radical prostatectomy (mostly extraperitoneal) patients was considered. Of these patients, 987 were evaluable. Results were stratified by the World Health Organization BMI category. Multivariate linear and logistic regression analysis was used to model the operating time, length of stay, positive surgical margins, and noncurable cancer. RESULTS: Of the 987 patients, 563 (57%) were overweight and 193 (19.6%) were obese. Of the 193 obesepatients, 152 (15.4%) had a BMI of 30 to <35 kg/m(2) (class I obesity), 28 (2.8%) a BMI of 35 to <40 kg/m(2) (class II), and 13 (1.3%) a BMI of ≥40 kg/m(2) (class III). No differences were found in the estimated blood loss, complications, PSM, pathologic stage, or biochemical recurrence across the BMI categories (6-month median follow-up). However, pelvic lymph node dissection was more commonly omitted and the nerve-sparing score was inferior in the obesemen. On multivariate analysis, a higher BMI was a significant predictor of a longer operating time. CONCLUSION:Obesemen can safely undergo laparoscopic radical prostatectomy or robot-assisted radical prostatectomy, although the ability to perform excellent nerve sparing appears to decrease with increasing obesity. Nevertheless, obesemen can expect perioperative and early oncologic outcomes comparable to those of normal weight men without an increased risk of perioperative complications.
Authors: Daniel J Moskovic; Hannah Alphs; Christian J Nelson; Farhang Rabbani; James Eastham; Karim Touijer; Bertrand Guillonneau; Peter T Scardino; John P Mulhall Journal: J Sex Med Date: 2010-08-19 Impact factor: 3.802
Authors: Daniel J Moskovic; Hugh J Lavery; Jamil Rehman; Fatima Nabizada-Pace; Jonathan Brajtbord; David B Samadi Journal: Can J Urol Date: 2010-08 Impact factor: 1.344
Authors: Christopher L Amling; Robert H Riffenburgh; Leon Sun; Judd W Moul; Raymond S Lance; Leo Kusuda; Wade J Sexton; Douglas W Soderdahl; Timothy F Donahue; John P Foley; Andrew K Chung; David G McLeod Journal: J Clin Oncol Date: 2003-12-22 Impact factor: 44.544
Authors: Stephen J Freedland; William J Aronson; Christopher J Kane; Joseph C Presti; Christopher L Amling; David Elashoff; Martha K Terris Journal: J Clin Oncol Date: 2003-12-22 Impact factor: 44.544
Authors: Christopher Goßler; Matthias May; Bernd Rosenhammer; Johannes Breyer; Gjoko Stojanoski; Steffen Weikert; Sebastian Lenart; Anton Ponholzer; Christina Dreissig; Maximilian Burger; Christian Gilfrich; Johannes Bründl Journal: Cent European J Urol Date: 2020-12-03
Authors: Daniel D Shapiro; John W Davis; Wendell H Williams; Brian F Chapin; John F Ward; Curtis A Pettaway; Justin R Gregg Journal: BJUI Compass Date: 2021-09-27
Authors: Rafael Rocha Tourinho-Barbosa; Marcos Tobias-Machado; Adalberto Castro-Alfaro; Gabriel Ogaya-Pinies; Xavier Cathelineau; Rafael Sanchez-Salas Journal: Arab J Urol Date: 2017-12-14